Cooperative inhibitory effects of antisense oligonucleotide of cell adhesion molecules and cimetidine on cancer cell adhesion

Table 1 Sequences of ASON and primers

Name		Sequence	Length
ASON
E-selectin		5’-TTCCCCAGATGCACCTGTTT-3’
ICAM-1		5’-CCCCCACCACTTCCCCTCTC-3’
Control		5’-GCCGAGGTCCATGTCGTACGC-3’
primer
E-selectin	Forward:	5’-AAAATGTTCAAGCCTGGCAGTTCC-3’
	Reverse:	5’-GTGGTGATGGGTGTTGCGGTTTCA-3’	509 bp
ICAM-1	Forward:	5’-CACAAGCCACGCCTCCCTGAACCTA-3’
	Reverse:	5’-TGTGGGCCTTTGTGTTTTGATGCTA-3’	458 bp
β-actin	Forward:	5’-CTGTCTGGCGGCACCACCAT-3’
	Reverse:	5’-GCAACTAAGTCATAGTCCGC-3’	250 bp

Table 2 Adhesion rate of endothelial cells transfected by E-selectin and ICAM-1 ASON to tumor cells (^-χ±s)%

Group	I	II	III	IV	V
E-selectin/HepG2	17.7 ± 0.9a	80.4 ± 6.2	58.9 ± 2.7	38.0 ± 5.0a	24.1 ± 1.5a
E-selectin/BEL7404	8.1 ± 1.0a	75.9 ± 0.6	52.2 ± 2.4a	26.7 ± 1.6a	17.4 ± 1.1ab
E-selectin/Ls-174-t	16.0 ± 1.6a	77.9 ± 5.7	53.9 ± 2.6a	43.1 ± 1.7a	29.5 ± 2.6ab
ICAM-1/HepG2	5.0 ± 1.3a	71.0 ± 2.4	68.6 ± 1.8	69.0 ± 1.4	67.3 ± 2.2 a
ICAM-1/BEL7404	3.0 ± 0.9a	65.9 ± 4.1	63.6 ± 5.0	63.5 ± 4.0	64.7 ± 1.7
ICAM-1/Ls-174-t	5.8 ± 0.8a	63.0 ± 2.0	63.4 ± 1.2	64.5 ± 1.8	62.8 ± 1.3

(1) I: Basal, II:TNF-α, III: Cimetidine, IV: Lipo-ASON, V: Lipo-ASON/Cimetidine. (2)

^aP < 0.05, vs groupII;

^bP < 0.05, group V vs group IV.